Wilander E - Search Results

1

Risk of cervical cancer and geographical variations of human papillomavirus 16 E6 polymorphisms.

Zehbe I, Voglino G, Delius H, Wilander E, Tommasino M. Zehbe I, et al. Among authors: wilander e. Lancet. 1998 Oct 31;352(9138):1441-2. doi: 10.1016/S0140-6736(05)61263-9. Lancet. 1998. PMID: 9807995 No abstract available.

2

Codon 72 polymorphism of p53 and its association with cervical cancer.

Zehbe I, Voglino G, Wilander E, Genta F, Tommasino M. Zehbe I, et al. Among authors: wilander e. Lancet. 1999 Jul 17;354(9174):218-9. doi: 10.1016/S0140-6736(99)01914-5. Lancet. 1999. PMID: 10421306

3

p53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development.

Zehbe I, Voglino G, Wilander E, Delius H, Marongiu A, Edler L, Klimek F, Andersson S, Tommasino M. Zehbe I, et al. Among authors: wilander e. Cancer Res. 2001 Jan 15;61(2):608-11. Cancer Res. 2001. PMID: 11212257

4

Human papillomavirus 16 E6 polymorphisms in cervical lesions from different European populations and their correlation with human leukocyte antigen class II haplotypes.

Zehbe I, Tachezy R, Mytilineos J, Voglino G, Mikyskova I, Delius H, Marongiu A, Gissmann L, Wilander E, Tommasino M. Zehbe I, et al. Among authors: wilander e. Int J Cancer. 2001 Dec 1;94(5):711-6. doi: 10.1002/ijc.1520. Int J Cancer. 2001. PMID: 11745467

5

Human papillomavirus infection and invasive cervical neoplasia: a study of prevalence and morphology.

Zehbe I, Wilander E. Zehbe I, et al. Among authors: wilander e. J Pathol. 1997 Mar;181(3):270-5. doi: 10.1002/(SICI)1096-9896(199703)181:3<270::AID-PATH767>3.0.CO;2-R. J Pathol. 1997. PMID: 9155711 Review.

6

Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype.

Zehbe I, Wilander E, Delius H, Tommasino M. Zehbe I, et al. Among authors: wilander e. Cancer Res. 1998 Feb 15;58(4):829-33. Cancer Res. 1998. PMID: 9485042

7

Two consensus primer systems and nested polymerase chain reaction for human papillomavirus detection in cervical biopsies: A study of sensitivity.

Zehbe I, Wilander E. Zehbe I, et al. Among authors: wilander e. Hum Pathol. 1996 Aug;27(8):812-5. doi: 10.1016/s0046-8177(96)90454-2. Hum Pathol. 1996. PMID: 8760015

8

High risk HPV persists after treatment of genital papillomavirus infection but not after treatment of cervical intraepithelial neoplasia.

Strand A, Wilander E, Zehbe I, Rylander E. Strand A, et al. Among authors: wilander e. Acta Obstet Gynecol Scand. 1997 Feb;76(2):140-4. doi: 10.3109/00016349709050070. Acta Obstet Gynecol Scand. 1997. PMID: 9049287 Free article.

9

Nonisotopic ELISA-based detection of human papillomavirus-amplified DNA.

Zehbe I, Wilander E. Zehbe I, et al. Among authors: wilander e. Mod Pathol. 1997 Mar;10(3):188-91. Mod Pathol. 1997. PMID: 9071725

10

Overriding of cyclin-dependent kinase inhibitors by high and low risk human papillomavirus types: evidence for an in vivo role in cervical lesions.

Zehbe I, Rätsch A, Alunni-Fabbroni M, Burzlaff A, Bakos E, Dürst M, Wilander E, Tommasino M. Zehbe I, et al. Among authors: wilander e. Oncogene. 1999 Apr 1;18(13):2201-11. doi: 10.1038/sj.onc.1202549. Oncogene. 1999. PMID: 10327066

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

280 results

Search Page

Filters